Literature DB >> 27755097

Noninvasive Failure in De Novo Acute Hypoxemic Respiratory Failure: High Positive End-Expiratory Pressure-Low Pressure Support, i.e., "Inverted Settings"?

Fabrice Petitjeans1, Luc Quintin.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27755097     DOI： 10.1097/CCM.0000000000001967

Source DB:  PubMed          Journal:  Crit Care Med        ISSN： 0090-3493            Impact factor:   7.598


× No keyword cloud information.
  5 in total

Review 1.  Hypothesis: Fever control, a niche for alpha-2 agonists in the setting of septic shock and severe acute respiratory distress syndrome?

Authors:  F Petitjeans; S Leroy; C Pichot; A Geloen; M Ghignone; L Quintin
Journal:  Temperature (Austin)       Date:  2018-05-22

Review 2.  Building on the Shoulders of Giants: Is the use of Early Spontaneous Ventilation in the Setting of Severe Diffuse Acute Respiratory Distress Syndrome Actually Heretical?

Authors:  Fabrice Petitjeans; Cyrille Pichot; Marco Ghignone; Luc Quintin
Journal:  Turk J Anaesthesiol Reanim       Date:  2018-09-01

3.  Clinical Practice: Should we Radically Alter our Sedation of Critical Care Patients, Especially Given the COVID-19 Pandemics?

Authors:  D Longrois; F Petitjeans; O Simonet; M de Kock; M Belliveau; C Pichot; Th Lieutaud; M Ghignone; L Quintin
Journal:  Rom J Anaesth Intensive Care       Date:  2021-01-04

4.  How should dexmedetomidine and clonidine be prescribed in the critical care setting?

Authors:  Dan Longrois; Fabrice Petitjeans; Olivier Simonet; Marc de Kock; Marc Belliveau; Cyrille Pichot; Thomas Lieutaud; Marco Ghignone; Luc Quintin
Journal:  Rev Bras Ter Intensiva       Date:  2022-01-24

Review 5.  A Centrally Acting Antihypertensive, Clonidine, Sedates Patients Presenting With Acute Respiratory Distress Syndrome Evoked by Severe Acute Respiratory Syndrome-Coronavirus 2.

Authors:  Fabrice Petitjeans; Jean-Yves Martinez; Marc Danguy des Déserts; Sandrine Leroy; Luc Quintin; Jacques Escarment
Journal:  Crit Care Med       Date:  2020-10       Impact factor: 9.296
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.